stockrow
Friday 6 November 2026
Export SEPN’s income statement to Excel — free account
Septerna, Inc.
SEPN Healthcare Biotechnology
Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.
- Revenue
- +22,375.6%
- EPS
- +48.2%
- Free cash flow
- −9.01%
Quarter to June 2026, against a year earlier
49.90
2.55
+5.39%
Follow SEPN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | 1 | 46 | 99 | +1,644.5% | 96 | 74 | 50 | +3.0% | |
| Gross margin, % | — | — | — | — | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 0.0 pt | ||||||
| EBT | — | — | — | — | — | — | — | 5 | (72) | (49) | (23) | n/m | ||||||
| EBT margin, % | — | — | — | — | — | — | — | 3,225.83 | (6,725.21) | (106.35) | (23.17) | (3,332.2) pt | ||||||
| Net income | — | — | — | — | — | — | — | 4 | (72) | (49) | (24) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.08 | 0.11 | 1.04 | 2.20 | +264.2% | |||||
| Earnings | — | — | — | — | — | — | — | 0.29 | (7.26) | (1.10) | (0.54) | n/m | ||||||
| Cash flow | — | — | — | — | — | — | — | (20.07) | (6.82) | 2.49 | 2.35 | n/m | ||||||
| Capex | — | — | — | — | — | — | — | 11.47 | 2.07 | 0.27 | 0.26 | (84.6%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (8.61) | (4.75) | 2.76 | 2.61 | n/m | ||||||
| Book value | — | — | — | — | — | — | — | (19.89) | 42.47 | 8.63 | 8.59 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | 2 | 10 | 44 | 45 | +379.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 58.37 | 210.70 | 26.85 | 21.84 | 98.6 | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.54 | 3.23 | 5.58 | 1.3 | ||||||
| EV/Sales | — | — | — | — | — | — | — | (87.31) | (115.74) | 18.34 | 18.07 | (61.6) | ||||||
| EV/FCF | — | — | — | — | — | — | — | 2.21 | 2.65 | 6.90 | 15.20 | 3.9 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (39) | (67) | 110 | 106 | n/m | |||||
| Capex | — | — | — | — | — | — | — | 22 | 21 | 12 | 12 | (26.4%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (17) | (47) | 122 | 118 | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 106 | 344 | 324 | 317 | +75.0% | |||||
| Net debt | — | — | — | — | — | — | — | (88) | (351) | (391) | (372) | +110.2% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | (38) | 420 | 382 | 387 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (24.45) | (9.29) | (4.94) | (9.3) pt | |||||
| ROIC | — | — | — | — | — | — | — | 0.00 | (73.08) | 0.00 | (189.01) | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | (37.62) | (12.19) | (6.34) | (12.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 75 | 130 | — | +73.3% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.01 | 0.35 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 25 Oct 2026
Septerna, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VCEL Vericel Corporation | $2.7B | 77.8× | 72.9× | +26.47% (above 0%: growing) | +180.00% (above 0%: growing) | −19.39% (below 0%: shrinking) | 73.34% | 14.27% | Compare |
| PVLA Palvella Therapeutics, Inc. | $2.3B | — (loss-making) | — (loss-making) | −99.09% (below 0%: shrinking) | n/m | −136.38% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| SEPN Septerna, Inc. | $2.2B | — (loss-making) | — (loss-making) | +22,375.63% (above 0%: growing) | n/m | −9.01% (below 0%: shrinking) | 100.00% | (62.95%) | |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | $2.2B | — (loss-making) | — (loss-making) | −95.35% (below 0%: shrinking) | +198.85% (above 0%: growing) | +18.22% (above 0%: growing) | 25.95% | (982.91%) | Compare |
| AUPH Aurinia Pharmaceuticals Inc | $2.2B | 6.8× | 17.6× | +13.93% (above 0%: growing) | 0.00% | +4.41% (above 0%: growing) | 90.08% | 40.74% | Compare |
| VERA Vera Therapeutics, Inc. | $2.2B | — (loss-making) | — | — | n/m | −82.47% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IMNM Immunome, Inc. | $2.1B | — (loss-making) | — (loss-making) | +69.84% (above 0%: growing) | n/m | −26.96% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| BHVN Biohaven Ltd. | $2.1B | — (loss-making) | — (loss-making) | +131.43% (above 0%: growing) | n/m | +26.55% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ZYME Zymeworks Inc. | $2.0B | — (loss-making) | 26.0× | −90.58% (below 0%: shrinking) | n/m | −385.53% (below 0%: shrinking) | (497.71%) | (918.95%) | Compare |
| Median of peers | $2.2B | — | 26.0× | +13.93% | +180.00% | −23.17% | 49.65% | 0.00% |
Pay and ownership Proxy statement filed 30 April 2026
Ownership
Directors and executive officers, together
5.80%
Entities Affiliated with Third Rock Ventures
23.30%
Entities Affiliated with RA Capital
15.60%
Driehaus Capital Management LLC
10.40%
Samsara BioCapital LP
6.20%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement
Septerna, Inc. (SEPN) Latest News
11 May
9 Mar
10 Jan
10 Nov
9 Oct
29 Sep
SEPN metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share